IP Library Granted Patent US 8,715,939
Granted Patent B2
US 8,715,939 · App. 13/253,819 · Granted May 6, 2014

Compositions, methods and kits to detect adenovirus nucleic acids

Inventors: Emily Ziegler (Milwaukee, WI); Jessica Townsend (Milwaukee, WI)
Assignee: Gen-Probe Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,715,939
App. No.
13/253,819
Granted
May 6, 2014
Kind
B2
Abstract

The disclosed invention is related to methods, compositions, kits and isolated nucleic acid sequences for targeting Adenovirus nucleic acid. Compositions include amplification oligomers and/or detection probe oligomers. Kits and methods comprise at least one of these oligomers.

Claims (13)

1. A method for specifically detecting an Adenovirus target nucleic acid in a sample comprising the steps of:

(a) contacting a sample suspected of containing at least an Adenovirus nucleic acid with

a first amplification primer comprising a nucleotide sequence consisting of SEQ ID NO: 27,

a second amplification primer comprising a nucleotide sequence consisting of SEQ ID NO: 28, and

a third amplification primer and a fourth amplification primer respectively comprising a nucleotide sequence consisting of SEQ ID NO: 25 and SEQ ID NO: 26, SEQ ID NO: 33 and SEQ ID NO: 34, or SEQ ID NO: 31 and SEQ ID NO: 26;

(b) providing conditions sufficient for generating an amplicon from an Adenovirus target nucleic acid present in said sample using said amplification primers from step (a); and

(c) providing conditions for detecting said amplicon and determining whether an Adenovirus target nucleic acid is present in said sample.

2. The method of claim 1 , wherein the third and fourth amplification primers respectively consist of the target hybridizing sequences as set forth in SEQ ID NO:31 and SEQ ID NO:26.

3. The method of claim 1 , wherein the third and fourth amplification primers respectively consist of the target hybridizing sequences as set forth in SEQ ID NO:33 and SEQ ID NO:34.

4. The method of claim 1 , wherein the third and fourth amplification primers respectively consist of the target hybridizing sequences as set forth in SEQ ID NO:25 and SEQ ID NO:26.

5. The method of claim 1 , wherein said detection step comprises contacting said amplification product with at least one detection probe configured to hybridize to a portion of said amplification product.

6. The method according to claim 5 , wherein the detection probe comprises or consists essentially of a target hybridizing sequence selected from the group consisting of SEQ ID Nos 17 to 24, 29, 30, 36, 37, 39 and 40 or a combination of two or more thereof.

7. The method according to claim 6 , wherein the detection probe comprises, consists of, or consists essentially of a sequence as set forth in SEQ ID No. 36 and/or SEQ ID No. 37.

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2011
From: ZIEGLER, EMILY; TOWNSEND, JESSICA
To: GEN-PROBE PRODESSE, INC., C/O GEN-PROBE INCORPORATED
Reel/Frame 027401/0312 →
Continuity (1)
Related Publication 20130089859A1 · Apr 11, 2013